TIFIA-IA polypeptide as well as coding nucleic acid and medical application thereof
By expressing and applying TIF-IA polypeptide and its encoding nucleic acids, it uses it to promote nucleolar stress mechanism to inhibit lipid synthesis, solving the problem of liver lipid accumulation in NAFLD, achieving the effect of reducing lipid accumulation, and providing NAFLD with New treatment options.
Patent Information
- Application Number
- CN202411099654.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-12
AI Technical Summary
The prior art is difficult to effectively reduce liver lipid accumulation, resulting in the progress of non-alcoholic fatty liver disease (NAFLD) into a more serious liver disease and lack of precise therapeutic targets.
By designing and expressing TIF-IA polypeptides and their encoding nucleic acids, they use their promotion of nucleolar stress mechanisms to inhibit lipid synthesis, thereby reducing lipid accumulation, providing potential predictors and treatment options.
Experiments show that TIF-IA polypeptide can significantly inhibit lipid synthesis and reduce lipid accumulation, and has important clinical treatment prospects, providing a new and precise treatment plan for NAFLD.
Smart Images

Figure CN118976125A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of bioengineering technology, and specifically relates to a TIF-IA polypeptide and its encoding nucleic acid and medical use. Background Art
[0002] Non-alcoholic fatty liver disease (NAFLD) is a metabolic syndrome characterized by excessive lipid accumulation, which is mainly induced by multiple factors such as obesity, type 2 diabetes, hyperlipidemia and other diseases. It represents a series of diseases ranging from simple lipid accumulation in the liver (hepatic steatosis) to more serious forms. As the disease progresses, it may further progress to cirrhosis and even liver cancer. Fatty liver disease has become a common disease worldwide. NAFLD is about 15% in my country and about 20% in Europe and the United States. The pathogenesis of NAFLD involves insulin resistance, liver fat accumulation, endoplasmic reticulum stress, mitochondrial dysfunction, changes in intestinal flora and activation of inflammatory pathways. Therefore, if the accumulation of liver lipids can be effectively reduced, it may help prevent NAFLD from progressing to more serious liver diseases. At present, the main treatments for NAFLD include non-drug treatment, drug treatment, surgical treatment and other means. For early patients, non-drug treatments are often used, such as lifestyle intervention and weight loss. As the disease progresses, the cause needs to be comprehensively considered to use symptomatic drug treatment, such as lipid-lowering drugs, insulin-sensitizing drugs, drugs that regulate oxidative stress and inflammation, anti-fibrosis drugs, and drugs that regulate intestinal flora and immune function. For patients who progress to cirrhosis or even liver cancer in the late stage, surgical treatments such as liver transplantation can be considered. Therefore, early and precise intervention is the key to treating NAFLD. Designing therapeutic drugs with more targets may be a research trend in future drug development.
[0003] TIF-IA is an RNA polymerase I transcription factor, a mammalian homolog of yeast Rrn3p, and plays a central role in the transcription of ribosomal DNA genes. TIF-IA is highly expressed in bone marrow, thyroid, testis, ovary, liver, lungs and other parts. Its expression is also crucial for maintaining nucleolar structure and cell viability. Activating liver RNA transcription can promote liver energy consumption, thereby reducing lipid accumulation in the liver. Therefore, TIF-IA can promote rRNA transcription, thereby promoting nucleolar stress, and to a certain extent affects cell fate, such as apoptosis, aging, autophagy and differentiation, in response to stress-induced damage. Through the development of the present invention, the occurrence mechanism of TIF-IA is explored, and a new precision treatment scheme is provided for NAFLD. Summary of the invention
[0004] In view of the deficiencies in the prior art, the purpose of the present invention is to provide a TIF-IA polypeptide and its encoding nucleic acid and medical uses, which have great prospects in preparing potential predictive indicators and candidate drugs for NAFLD.
[0005] In the first aspect of the present invention, a TIF-IA polypeptide having an amino acid sequence as shown in SEQ ID NO.1, a nucleic acid encoding the TIF-IA polypeptide, a vector comprising the nucleic acid, or a composition comprising the TIF-IA polypeptide is provided for use in the preparation of a drug for preventing and / or treating non-alcoholic fatty liver disease.
[0006] The second aspect of the present invention provides a TIF-IA polypeptide having an amino acid sequence as shown in SEQ ID NO.1, a nucleic acid encoding the TIF-IA polypeptide, a vector comprising the nucleic acid, or a composition comprising the TIF-IA polypeptide for use in predictive scoring of non-alcoholic fatty liver disease.
[0007] Furthermore, the nucleotide sequence of the nucleic acid encoding the TIF-IA polypeptide is shown in SEQ ID NO.2.
[0008] The third aspect of the present invention provides a nucleic acid encoding a TIF-IA polypeptide, wherein the amino acid sequence of the TIF-IA polypeptide is shown in SEQ ID NO.1, and the nucleotide sequence of the nucleic acid is shown in SEQ ID NO.2.
[0009] Beneficial effects: The present invention utilizes bioengineering technology to genetically recombinant a DNA sequence corresponding to a polypeptide into the pcDNA3.1(+) eukaryotic expression vector. After enzyme digestion and sequence analysis prove that the recombination is successful, the eukaryotic expression recombinant polypeptide is transfected into liver cells, and immunoblotting proves the protein expression of the polypeptide, thus achieving the recombination of the polypeptide. The lipid metabolism promoting function of the polypeptide is studied, and the experiment shows that TIF-IA can inhibit lipid synthesis by promoting nucleolar stress, thereby reducing lipid accumulation. It has a very important development prospect for the clinical treatment of NAFLD. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] In order to more clearly illustrate the specific implementation methods of the present application or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0011] Figure 1: is the immunohistochemical result diagram of TIF-IA polypeptide in normal liver and NAFLD patient liver tissue in Example 1 of the present invention, wherein the upper figure is the representative immunohistochemical staining result of TIF-IA in normal liver and NAFLD liver tissue, and the lower figure is the statistical analysis result of the positive ratio of TIF-IA in normal and NAFLD liver tissue (**, P<0.01, statistically significant);
[0012] Figure 2 This is a diagram showing the results of immunoblotting detection of the expression of polypeptide molecules in hepatocytes after transfection of the TIF-IA polypeptide recombinant vector in Example 2 of the present invention;
[0013] Figure 3 It is an Oil Red staining image showing that TIF-IA polypeptide reduces fat accumulation in the palmitic acid stimulated HepG2 group in Example 3 of the present invention; the upper figure is a representative graphical representation of lipid deposition in the control and TIF-IA polypeptide recombinant vector transfected HepG2 cells, and the lower figure is a statistical analysis result of lipid accumulation levels in the control and TIF-IA polypeptide recombinant vector transfected HepG2 cells (***, P<0.001, statistically significant). DETAILED DESCRIPTION
[0014] The present application will be further described below in conjunction with the embodiments and examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. In addition, it should be understood that after reading the content taught in the present application, those skilled in the art may make various changes or modifications to the present application, and these equivalent forms also fall within the protection scope of the claims attached to the present application.
[0015] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.
[0016] The amino acid sequence of the TIF-IA polypeptide in the present application is shown in the sequence listing SEQ ID NO.1, and is as follows:
[0017] 1 maapllhtrl pgdaaassssa vkklgasrtg isnmralend ffnspprktv rfggtvtevl
[0018] 61 lkykkgetnd fellknqlld pdikrlpwln rsqtvveeyl aflgnlvsaq tvflrpclsm
[0019] 121 iashfvpprv iikegdvdvs dsddeddnlp anfdtchral qiiaryvpst pwflmpilve
[0020] 181 kfpfvrkser
[0021] The cDNA sequence of the TIF-IA polypeptide in this application is shown in Sequence Listing SEQ ID NO.2, specifically as follows:
[0022] 1 ATGGCGGCGC CTCTCCTCCA CACCCGGTTG CCTGGTGACG CTGCCGCCTC CTCAAGCGCA
[0023] 61 GTAAAAAAGC TCGGCGCTAG TAGGACCGGC ATCTCTAATA TGAGGGCACT CGAGAACGAT
[0024] 121 TTCTTTAATA GCCCTCCGCG AAAAACTGTA CGATTTGGTG GAACAGTCAC AGAGGTCCTG
[0025] 181 TTGAAGTATA AGAAAGGTGA GACCAACGAC TTTGAATTGC TCAAAAACCA ACTCCTTGAC
[0026] 241 CCTGACATAA AGAGGTTGCC ATGGCTTAAT AGGAGTCAAA CGGTCGTAGA AGAATATTTG
[0027] 301 GCATTTTTGG GCAACCTTGT ATCTGCACAG ACAGTGTTCC TGCGCCCTTG CTTGAGTATG
[0028] 361 ATCGCGTCCC ACTTCGTGCC GCCAAGAGTT ATCATTAAAG AGGGGGATGT TGATGTGTCC
[0029] 421 GATAGCGATG ATGAGGACGA CAATCTGCCG GCTAACTTTG ATACATGTCA CCGGGCGCTG
[0030] 481 CAAATCATTG CGAGATATGT CCCCTCTACC CCGTGGTTCT TGATGCCCAT CTTGGTAGAG
[0031] 541 AAATTCCCAT TCGTCAGAAA ATCCGAACGA
[0032] The present application discovered through experiments that the polypeptide of the sequence shown in SEQ ID NO.1 can inhibit lipid synthesis by promoting nucleolar stress, thereby reducing lipid accumulation.
[0033] The following are some specific embodiments.
[0034] Example 1: Expression of TIF-IA polypeptide in normal subjects and NAFLD patients by immunohistochemistry
[0035] The liver tissue was sliced and dried. It was repeatedly soaked in xylene and anhydrous ethanol and washed with water. Antigen repair; blocked with hydrogen peroxide for 20 minutes, washed three times with PBS; serum blocked with enzyme-labeled goat anti-rabbit IgG complex, incubated at 37°C for 20 minutes, washed three times with PBS; primary antibody incubation, overnight at 4°C; secondary antibody incubation, incubated at room temperature for 1 hour, washed three times with PBS; DAB color development; counterstaining of cell nuclei; dehydration and sealing; staining observation. The results of immunohistochemistry showed that the expression of TIFIA in the liver tissue of the NAFLD patient group was significantly decreased compared with that of the normal population, suggesting that the downregulation of nucleolus and nucleolar stress function is associated with the adverse accumulation of fat in the liver of NAFLD patients ( Figure 1 ).
[0036] Example 2: Construction of TIF-IA polypeptide recombinant cDNA and expression detection in liver cancer cells
[0037] 1. Construction of eukaryotic expression vector for polypeptide
[0038] The nucleic acid sequence (SEQ ID NO.2) expressing the polypeptide of the sequence shown in SEQ ID NO.1 was obtained by entrusting Shanghai Shenggong Company to perform gene synthesis services. After purification, it was double-digested with ECOR1 and AgeI, and the fragment was recovered using a gel DNA recovery kit. The plasmid pcDNA3.1 (+) was digested with the same enzyme and DNA was recovered at the same time. Then, the recovered polypeptide nucleic acid DNA and plasmid DNA were mixed and incubated at 16°C overnight with T4 DNA ligase. The obtained recombinant plasmid was transformed into competent Escherichia coli, and then the bacteria were picked, shaken, and the plasmid was extracted, that is, the plasmid DNA expressing the polypeptide of the sequence shown in SEQ ID NO.1 was obtained.
[0039] 2. Expression and Identification of TIF-IA Peptide
[0040] HepG2 cells were plated in a six-well plate, and when the cells adhered to the wall and the density reached about 70%-90%, the cell medium was replaced with 2 ml serum-free, double-antibody Opti-DMEM, and two 1.5 ml EP tube solutions were prepared (100 ul Opti-DMEM + 10 ullip2000 was added to 1 tube; 1.2 u plasmid + 1.2 ug PAX2 + 0.6 ug PMD2G + 100 ul Opti-DMEM was added to 1 tube) and allowed to stand for about 15 min, and the two tubes of solution were mixed and added to the cells. The medium was replaced after 6 hours, and the cells were collected after 48 hours, washed with PBS for 3 times, and the immunoprecipitation lysis buffer (RIPA + CM + PI) was added to lyse the cells, and the cells were allowed to stand for 30 min, ground on ice, centrifuged, and then Loading Buffer (about 1 / 4 of the lysis buffer) was added, and heated at 100°C for about 7 min, and Western blot was performed. Blotting verification, after electrophoresis (80V), transfer (300mA), blocking for 2h, primary antibody incubation, membrane washing, secondary antibody incubation, membrane washing, and finally using Bio-Rad developer to develop the target band and take photos, the immunoblotting results showed that this polypeptide can be successfully expressed in hepatocytes, with a molecular weight of 22kDa, which is consistent with the prediction ( Figure 2 ).
[0041] Example 3: TIF-IA polypeptide alleviates oil red staining of fat accumulation in the palmitic acid-stimulated HepG2 group
[0042] HepG2 cells were cultured in a 6-well plate, stimulated with palmitic acid (0.4 mM) for 24 h, the culture medium was discarded, the cells were washed three times with PBS, fixed with 4% paraformaldehyde for 30 min, the paraformaldehyde was discarded, the cells were stained with oil red dye in the dark for 20 min, rinsed with isopropanol for a few seconds, and then washed three times with PBS. The cells were observed under a microscope. Figure 3 The results showed that the introduction of TIF-IA peptide can significantly inhibit the accumulation of lipids in hepatocytes induced by palmitic acid stimulation, suggesting that it has the ability to alleviate abnormal lipid metabolism and abnormal lipid accumulation in hepatocytes ( Figure 3 ).
Claims
1. Use of a TIF-IA polypeptide having an amino acid sequence as shown in SEQ ID NO.1, a nucleic acid encoding the TIF-IA polypeptide, a vector comprising the nucleic acid, or a composition comprising the TIF-IA polypeptide in the preparation of a drug for preventing and / or treating non-alcoholic fatty liver disease.
2. Use of a TIF-IA polypeptide having an amino acid sequence as shown in SEQ ID NO.1, a nucleic acid encoding the TIF-IA polypeptide, a vector comprising the nucleic acid, or a composition comprising the TIF-IA polypeptide in predictive scoring for non-alcoholic fatty liver disease.
3. The use according to claim 1 or 2, It is characterized in that The nucleotide sequence of the nucleic acid encoding the TIF-IA polypeptide is shown in SEQ ID NO.
2.
4. a nucleic acid, It is characterized in that The nucleic acid is a nucleic acid encoding a TIF-IA polypeptide, the amino acid sequence of the TIF-IA polypeptide is shown in SEQ ID NO.1, and the nucleotide sequence of the nucleic acid is shown in SEQ ID NO.2.
Citation Information
Patent Citations
Construction of SMAGP protein polypeptide and application of SMAGP protein polypeptide in resisting fatty liver disease activity
CN114933646A
Targeted inhibitor of RRN3P2 gene and application thereof
CN118147140A
Application of LRP1-beta chain oligopeptide in treatment of non-alcoholic fatty liver disease
CN118161595A
Encoding gene of EHD2 polypeptide, vector and medical application thereof
CN118956884A
RNA polymerase I transcription factor TIF-IA
US20020146801A1
